恩替卡韦
医学
肝硬化
替诺福韦
内科学
慢性肝炎
胃肠病学
HBeAg
乙型肝炎
病毒学
乙型肝炎病毒
拉米夫定
病毒
乙型肝炎表面抗原
人类免疫缺陷病毒(HIV)
出处
期刊:PubMed
日期:2015-06-01
卷期号:62 (140): 982-6
被引量:1
摘要
Entecavir and tenofovir are generally accepted as first-line therapeutic options in chronic hepatitis B. Both of them are potent and have high genetic barrier to viral resistance. Aim of this study was to compare the two-year efficacy of entecavir and tenofovir in treatment-naive chronic hepatitis B patients.Study was comprised 164 patients with treatment naïve chronic hepatitis or compensated liver cirrhosis. At least twenty four mouths of entecavir or tenofovir were given to all patients.Mean ALT levels, ALT normalization rates, mean HBV DNA levels, HBV DNA negativity rates and HBeAg negativity rates were not different in entecavir and tenofovir groups throughout the study. Mean serum creatinine levels were also similar between groups.Two-years of antiviral treatment of treatment-naïve patients with chronic hepatitis B or cirrhosis with entecavir or tenofovir were equally effective.
科研通智能强力驱动
Strongly Powered by AbleSci AI